Edwards Lifesciences (EW) Earnings Date & Reports

Key Takeaways

• Edwards Lifesciences reported third-quarter 2026 net sales of $1.72 billion, up about 10% from $1.55 billion a year earlier and ahead of the $1.68 billion consensus estimate.
• Adjusted earnings per share (EPS) rose 19% year over year to $0.80, beating analyst expectations of $0.74 by $0.06.
• Transcatheter Mitral and Tricuspid Therapies (TMTT) sales jumped 44% to $207 million, while Transcatheter Aortic Valve Replacement (TAVR) sales grew 8% to $1.24 billion.
• Management raised its full-year 2026 sales growth outlook to roughly 11.5% and lifted its adjusted EPS guidance to $2.97–$3.05.
• The company issued fourth-quarter 2026 guidance for sales of $1.67–$1.75 billion and adjusted EPS of $0.61–$0.69.
• For more on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated EW pages on Tickeron.
• To discover AI-driven trading strategies and automated stock-picking ideas, explore Tickeron's Trending AI Robots.

Earnings Context and Why It Matters

Edwards Lifesciences is a leading maker of structural heart devices, anchored by its TAVR franchise, which treats aortic stenosis without open-heart surgery. This quarterly earnings report matters because TAVR procedure volumes and the company's fast-growing TMTT portfolio are the core drivers of its long-term revenue trajectory. Investors also track margin execution closely, since Edwards has been phasing strategic investments in research and development (R&D) and selling, general, and administrative (SG&A) spending throughout the year. The third-quarter print arrived after a series of positive clinical and regulatory developments, including recent U.S. Food and Drug Administration (FDA) approvals, making this report a key test of whether momentum is converting into sustained financial growth.

Reported Results

Edwards Lifesciences reported third-quarter 2026 net sales of $1,715.5 million, up roughly 10% from $1,553.1 million in the prior-year period and above the $1.68 billion consensus. On a Generally Accepted Accounting Principles (GAAP) basis, diluted EPS was $0.53, up from $0.50 a year earlier. Adjusted EPS came in at $0.80, a 19% increase over the prior year's $0.67 and $0.06 above the $0.74 analyst estimate.

Segment performance underscored the company's two growth engines. TAVR sales rose 8.0% to $1.24 billion, or 8.8% on a constant-currency basis, with similar growth in the U.S. and internationally. TMTT sales surged 44.0% to $207 million, or 45.6% in constant currency. Surgical sales increased 2.5% to $264 million. GAAP gross margin improved to 78.5% from 77.8%, while adjusted operating margin expanded to 30.3% from 27.5%.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Edwards Lifesciences, it offers a structured way to surface comparable opportunities and monitor evolving market conditions.

Market Reaction and Investor Sentiment

The results delivered a clean beat on both the top and bottom lines, with adjusted EPS exceeding consensus by $0.06 and revenue topping estimates by roughly $40 million. The combination of stronger-than-expected TAVR and TMTT growth and a raised full-year outlook generally supports a constructive interpretation among investors. Sentiment heading into the release had already been bolstered by positive trial data and recent FDA approvals across the structural heart portfolio. The key question for the market is whether the upwardly revised guidance and continued TMTT acceleration justify the stock's valuation, with analysts' price targets having trended higher in recent weeks.

Forward Outlook and Key Factors to Monitor

Following the strong third quarter, Edwards raised its full-year 2026 sales growth guidance to approximately 11.5%, up from a prior range of 10% to 11%. It also lifted TAVR growth guidance to 9% to 9.5% and raised its TMTT sales outlook to $780 million to $790 million. Full-year adjusted EPS guidance was increased to $2.97 to $3.05, from $2.95 to $3.05.

For the fourth quarter, the company projects total sales between $1.67 billion and $1.75 billion and adjusted EPS of $0.61 to $0.69. Investors will be watching whether TAVR procedure volumes sustain their momentum and whether TMTT's rapid expansion continues into 2027.

Key factors to monitor include the pace of adoption of newly approved devices, the impact of recent Medicare coverage determinations on TAVR access, and margin progression as planned R&D and SG&A investments phase through the year. Management has indicated it will outline 2027 and longer-term guidance at its December 2026 investor conference, making that event an important catalyst for the stock's narrative.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations